The closing price of Pediatrix Medical Group Inc (NYSE: MD) was $9.15 for the day, up 1.10% from the previous closing price of $9.05. In other words, the price has increased by $+0.10 from its previous closing price. On the day, 567318 shares were traded. MD stock price reached its highest trading level at $9.27 during the session, while it also had its lowest trading level at $9.03.
Ratios:
Our analysis of MD’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.33 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.77. For the most recent quarter (mrq), Quick Ratio is recorded 1.20 and its Current Ratio is at 1.38. In the meantime, Its Debt-to-Equity ratio is 0.83 whereas as Long-Term Debt/Eq ratio is at 0.83.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, SVB Leerink on September 27, 2021, initiated with a Mkt Perform rating and assigned the stock a target price of $29.
Deutsche Bank Downgraded its Hold to Sell on October 19, 2020, whereas the target price for the stock was revised from $20 to $12.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 14 when Swift James D sold 5,764 shares for $9.58 per share. The transaction valued at 55,219 led to the insider holds 90,874 shares of the business.
Moore Mary Ann E sold 1,150 shares of MD for $11,063 on Dec 14. The EVP, General Counsel & Sec now owns 15,730 shares after completing the transaction at $9.62 per share. On Dec 14, another insider, Moore Mary Ann E, who serves as the EVP, General Counsel & Sec of the company, sold 970 shares for $9.62 each. As a result, the insider received 9,331 and left with 81,385 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MD now has a Market Capitalization of 761.31M and an Enterprise Value of 1.29B. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.39 while its Price-to-Book (P/B) ratio in mrq is 0.79. Its current Enterprise Value per Revenue stands at 0.64 whereas that against EBITDA is 43.00.
Stock Price History:
Over the past 52 weeks, MD has reached a high of $16.00, while it has fallen to a 52-week low of $7.70. The 50-Day Moving Average of the stock is 9.31, while the 200-Day Moving Average is calculated to be 11.79.
Shares Statistics:
MD traded an average of 792.92K shares per day over the past three months and 887.15k shares per day over the past ten days. A total of 84.12M shares are outstanding, with a floating share count of 83.02M. Insiders hold about 1.31% of the company’s shares, while institutions hold 98.46% stake in the company. Shares short for MD as of Feb 15, 2024 were 3.13M with a Short Ratio of 3.95, compared to 2.89M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.72% and a Short% of Float of 5.25%.
Earnings Estimates
The firm’s stock currently is rated by 7 analysts. On average, analysts expect EPS of $0.2 for the current quarter, with a high estimate of $0.25 and a low estimate of $0.16, while EPS last year was $0.23. The consensus estimate for the next quarter is $0.34, with high estimates of $0.4 and low estimates of $0.3.
Analysts are recommending an EPS of between $1.31 and $1.16 for the fiscal current year, implying an average EPS of $1.24. EPS for the following year is $1.29, with 7 analysts recommending between $1.36 and $1.12.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 7 analysts. It ranges from a high estimate of $510.4M to a low estimate of $492.1M. As of the current estimate, Pediatrix Medical Group Inc’s year-ago sales were $490.78M, an estimated increase of 2.10% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $509.89M, an increase of 1.90% less than the figure of $2.10% in the same quarter last year. There is a high estimate of $514.69M for the next quarter, whereas the lowest estimate is $503.6M.
A total of 7 analysts have provided revenue estimates for MD’s current fiscal year. The highest revenue estimate was $2.07B, while the lowest revenue estimate was $2.01B, resulting in an average revenue estimate of $2.04B. In the same quarter a year ago, actual revenue was $1.99B, up 2.40% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $2.11B in the next fiscal year. The high estimate is $2.15B and the low estimate is $2.07B. The average revenue growth estimate for next year is up 3.50% from the average revenue estimate for this year.
